June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Botulinum toxin injection in the palpebral lacrimal gland for the management of epiphora
Author Affiliations & Notes
  • Imtiaz A Chaudhry
    Houston Oculoplastics Associates, Memorial Herman Med Plaza TX Med Ctr, Houston, TX
  • Farrukh A Shamsi
    Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Yonca O Arat
    University of Wisconsin, Madison, WI
  • Waleed A. Al-Rashed
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Osama Al-Sheikh
    King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • Milton Boniuk
    Baylor College of Medicine, Houston, TX
  • Footnotes
    Commercial Relationships Imtiaz Chaudhry, None; Farrukh Shamsi, None; Yonca Arat, None; Waleed Al-Rashed, Xeoman (S); Osama Al-Sheikh, None; Milton Boniuk, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4751. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Imtiaz A Chaudhry, Farrukh A Shamsi, Yonca O Arat, Waleed A. Al-Rashed, Osama Al-Sheikh, Milton Boniuk; Botulinum toxin injection in the palpebral lacrimal gland for the management of epiphora. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4751.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report our experience with Botulinum toxin injections into the palpebral lacrimal gland through transconjunctival approach in the management of epiphora due to different causes.

Methods: We reviewed our experience with transconjunctival Botulinum toxin injection (2.5 - 5 U) in the palpebral lacrimal galnd of 56 adult patients in the management of epiphora due to different causes. Some of the causes of epiphora in our patients included crockadile tears (gustatory) secondary to aberrant regeneration of the facial nerve after facial nerve palsy, epiphora despite patent functional nasolacrimal system, ideopathic hypersecretion, persistent partial epiphora despite successful lacrimal drainage sugery and reflex tearing due to different causes.

Results: Fourty-eight (86%) of our patients reported improvement from the Botulinum injections into their palpebral lacrimal gland through transconjunctival approach in the form of significantly decreased symptoms of epiphora. Patients remained symtpoms free between 2 to 6 months (average 4.4 month) after Botumlinum injection. Complications were low and inlcuded subconjunctival hemorrhage at the site of injection in 6 patients and transient diplopia in 2 patients and ptosis in 2 patients. Both the transient diplopia and ptosis resolved in 1 to 3 weeks in all patients.

Conclusions: Use of a single Botulinum toxin injection into the palpebral lobe of the lacrimal galnd through transconjunctival approach may be a viable option in adult patients with epiphora due to differnet causes with relatively mninimal complications.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×